Search research articles
Contact Us
Filters
Showing results (21-30 of 54) with videos related to
Page
of 6
Sort By:
Drugs & Aging
|
July 30, 2020
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
Sender Herschorn, David Staskin, Carol R Schermer, et al.
The Journal of Urology
|
February 19, 2020
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR
David Staskin, Jeffrey Frankel, Susann Varano, et al.
BMC Urology
|
August 21, 2010
Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
Linda Cardozo, Vik Khullar, Ahmed El-Tahtawy, et al.
The Journal of Urology
|
March 9, 2021
Reply by Authors
David Staskin, Jeffrey Frankel, Susann Varano, et al.
International Journal of Clinical Practice
|
December 17, 2020
Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study
Jeffrey Frankel, Susann Varano, David Staskin, et al.
The Journal of Urology
|
December 28, 2020
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)
David Staskin, Jeffrey Frankel, Susann Varano, et al.
Drugs & Aging
|
January 20, 2021
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
Susann Varano, David Staskin, Jeffrey Frankel, et al.
The Journal of Urology
|
May 6, 2024
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
David Staskin, Janet Owens-Grillo, Elizabeth Thomas, et al.
The Journal of Urology
|
May 22, 2020
Reply by Authors
David Staskin, Jeffrey Frankel, Susann Varano, et al.
International Urogynecology Journal
|
June 17, 2017
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
David Staskin, Sender Herschorn, Jonathan Fialkov, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 54) with videos related to
Sort By:
Page
of 6
Drugs & Aging
|
July 30, 2020
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
Sender Herschorn, David Staskin, Carol R Schermer, et al.
The Journal of Urology
|
February 19, 2020
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR
David Staskin, Jeffrey Frankel, Susann Varano, et al.
BMC Urology
|
August 21, 2010
Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
Linda Cardozo, Vik Khullar, Ahmed El-Tahtawy, et al.
The Journal of Urology
|
March 9, 2021
Reply by Authors
David Staskin, Jeffrey Frankel, Susann Varano, et al.
International Journal of Clinical Practice
|
December 17, 2020
Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study
Jeffrey Frankel, Susann Varano, David Staskin, et al.
The Journal of Urology
|
December 28, 2020
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)
David Staskin, Jeffrey Frankel, Susann Varano, et al.
Drugs & Aging
|
January 20, 2021
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
Susann Varano, David Staskin, Jeffrey Frankel, et al.
The Journal of Urology
|
May 6, 2024
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
David Staskin, Janet Owens-Grillo, Elizabeth Thomas, et al.
The Journal of Urology
|
May 22, 2020
Reply by Authors
David Staskin, Jeffrey Frankel, Susann Varano, et al.
International Urogynecology Journal
|
June 17, 2017
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
David Staskin, Sender Herschorn, Jonathan Fialkov, et al.
Page
of 6